Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702155 | 1.00 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 | |
| SCHEMBL2065565 | 1.00 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 | |
| SCHEMBL2518292 | 1.00 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 | |
| SCHEMBL2065563 | 1.00 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 | |
| SCHEMBL15195508 | 0.86 | HDAC2 (0.58) | HDAC2SMN1; SMN2FOLH1LMNA | |
| SCHEMBL10315742 | 0.86 | HDAC2 (0.58) | HDAC2SMN1; SMN2FOLH1LMNA | |
| SCHEMBL7969584 | 0.82 | HDAC2 (0.43) | HDAC2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL18618644 | 0.81 | HDAC2 (0.44) | HDAC2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL12601342 | 0.79 | HDAC2 (0.63) | HDAC2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL869683 | 0.79 | HDAC2 (0.63) | HDAC2SLC22A6HDAC3HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333697-B | Synthesis method of romidepsin | 深圳翰宇药业股份有限公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20220017538-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | ONKURE, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-11203602-B2 | Thioester prodrugs of macrocycles as inhibitors of histone deacetylases | ONKURE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3131550-B1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY WITH A HISTONE DEACETYLASE INHIBITOR | SIGNAL PHARM LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-2802340-B1 | ROMIDEPSIN FORMULATIONS AND USES THEREOF | CELGENE CORP (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317693-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | ONKURE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111333697-A | Synthesis method of romidepsin | 深圳翰宇药业股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| WO-2020125045-A1 | METHOD FOR SYNTHESIZING ROMIDEPSIN | 深圳翰宇药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-06-09 | — | — | US | disclosed |
| CN-111205350-A | Macrocyclic thioester prodrugs as histone deacetylase inhibitors | 恩库勒公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2009105284-A1 | METHODS OF PREPARATION OF MACROCYCLIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20090209616-A1 | PREPARATION OF ROMIDEPSIN | CELGENE CORPORATION | 2009-08-20 | — | — | US | disclosed |
| US-20090186382-A1 | Preparation of Romidepsin | CELGENE CORPORATION | 2009-07-23 | — | — | US | disclosed |
| US-20090105200-A1 | Combination therapy | GLOUCESTER PHARMACEUTICALS | 2009-04-23 | — | — | US | disclosed |
| WO-2009032352-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008127659-A2 | COMBINATION THERAPY FOR CANCER | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008091620-A2 | COMBINATION THERAPY COMPRISING ROMIDEPSIN AND I.A. BORTEZOMIB | GLOUCESTER PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008088331-A1 | METHODS FOR INCREASING LEVELS OF HUMAN FETAL HEMOGLOBIN | GLOUCESTER PHARMACEUTICALS (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008083288-A2 | PURIFICTION OF ROMIDEPSIN | GLOUCESTER PHARMACEUTICALS (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008083290-A1 | ROMIDEPSIN-BASED TREATMENTS FOR CANCER | GLOUCESTER PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105200-A1 | Combination therapy | MCL1, BCL3, PSMB5 | HDAC2 464/4885SLC22A6 3103/4885HDAC3 210/4885 |
| US-20090209616-A1 | PREPARATION OF ROMIDEPSIN | PTMA, PDIA6, MLN | HDAC2 3067/4885SLC22A6 1941/4885HDAC3 3026/4885 |
| US-11203602-B2 | Thioester prodrugs of macrocycles as inhibitors of histone deacetylases | HDAC11, HDAC1, HDAC10 | HDAC2 7/4885SLC22A6 2563/4885HDAC3 4/4885 |
| US-10676504-B2 | Method for preparing largazole analogs and uses thereof | CYP51A1, ADPRS, LPXN | HDAC2 362/4885SLC22A6 4465/4885HDAC3 114/4885 |
| US-20220017538-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | HDAC11, HDAC1, HDAC10 | HDAC2 7/4885SLC22A6 2563/4885HDAC3 4/4885 |
| US-20200317693-A1 | THIOESTER PRODRUGS OF MACROCYCLES AS INHIBITORS OF HISTONE DEACETYLASES | HDAC11, HDAC1, HDAC10 | HDAC2 7/4885SLC22A6 2563/4885HDAC3 4/4885 |
| US-20090186382-A1 | Preparation of Romidepsin | PTMA, PDIA6, MLN | HDAC2 3067/4885SLC22A6 1941/4885HDAC3 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.